Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP3

Circulation

Volumn 104, Issue 10, 2001, Pages 1176-1180

  Ma, Hong ^a   Hara, Akiyoshi ^a   Xiao, Chun Yang ^a   Okada, Yuji ^a   Takahata, Osamu ^a   Nakaya, Kazuhiro ^a   Sugimoto, Yukihiko ^b   Ichikawa, Atsushi ^b   Narumiya, Shuh ^b   Ushikubi, Fumitaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Hemorrhage; Platelets; Prostaglandins; Thrombosis; Thromboxane

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ARACHIDONIC ACID; CALCIUM; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E3 RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ARTICLE; BLEEDING TENDENCY; BLEEDING TIME; CALCIUM CELL LEVEL; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOGENESIS;

EID: 0035806894     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc3601.094003     Document Type: Article

References (31)

1. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides
2. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
3. Formation and release of prostaglandins by platelets in response to thrombin
4. Formation of prostaglandins during the aggregation of human blood platelets
5. Prostanoid production by human platelets: Redirection by the thromboxane synthetase inhibitor UK 37,248
6. 2
7. 2
8. Coronary tone modulation: Formation and actions of prostaglandins, endoperoxides, and thromboxanes
9. Atherosclerosis: An inflammatory disease
10. Release and activation of platelet latent TGF-β in blood clots during dissolution with plasmin
11. The bioactive phospholipid lysophosphatidic acid is released from activated platelets
12. Prostanoid receptors: Structures. Properties and functions
13. i in cDNA-transfected Chinese hamster ovary cells
14. 2 analogue, on human blood platelet behavior and vascular contractility
15. On the multiplicity of platelet prostaglandin receptors, I: Evaluation of competitive antagonism by aggregometry
16. 2 and hydantoin analogs
17. 2 on human gel-filtered platelets
18. Cyclic AMP turnover in response to prostaglandins in intact platelets: Evidence for separate stimulatory and inhibitory prostaglandin receptors
19. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues
20. 3
21. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: An analysis using specific agonists for the respective EPs
22. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells
23. 2 receptor abnormality: Defective signal transduction with normal binding activity
24. 2+ indicators with greatly improved fluorescence properties
25. Bleeding time in laboratory animals, II: A comparison of different assay conditions in rats
26. Intravenous arachidonate in the mouse: A model for the evaluation of antithrombotic drugs
27. Mouse antithrombotic assay: A simple method for the evaluation of antithrombotic agents in vivo
28. 2 both stimulates and inhibits adenyl cyclase on platelets: Comparison of effects on cloned EP4 and EP3 prostaglandin receptor subtypes
29. Thromboxane agonism and antagonism in a mouse sudden death model
30. 2
31. 2 receptor in a dominantly inherited bleeding disorder